Clinical Trial Update: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AZD2171 for recurrent or Stage IV melanoma has completed enrollment with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Lentiginous Malignant Melanoma
• Ciliary Body and Choroid Mal Melanoma
• Ciliary Body and Choroid Malanoma
• Intraocular Melanoma
• Iris Melanoma
• Lentigo Maligna Malignant Melanoma
• Melanoma
• Stage Intraocular Melanoma
• Superficial Spreading Malignant Melanoma

Drugs mentioned

• AZD2171 (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size | Phase 2 | Status: COMPLETED | Results posted: 2015-06-23